Kristen Hartman – Page 14 – Advanced Targeting Systems

Orexin A alleviates LPS-induced acute lung injury by inhibiting macrophage activation through JNK-mediated autophagy

Nie Y, Liang J, Sun J, Li J, Zhai X, Zhao P (2023) Orexin A alleviates LPS-induced acute lung injury by inhibiting macrophage activation through JNK-mediated autophagy. Int Immunopharmacol 124(Pt B):111018. doi: 10.1016/j.intimp.2023.111018 PMID: 37801969 Objective: To investigate the crosstalk between the central nervous system and immune response through the inflammatory response caused by lung […]

Orexin A alleviates LPS-induced acute lung injury by inhibiting macrophage activation through JNK-mediated autophagy Read More »

Lesions of kndy and kiss1r neurons in the arcuate nucleus produce different effects on lh pulse patterns in female sheep

Kristen Hartman

Goodman RL, Moore AM, Onslow K, Hileman SM, Hardy SL, Bowdridge EC, Walters BA, Agus S, Griesgraber MJ, Aerts EG, Lehman MN, Coolen LM (2023) Lesions of kndy and kiss1r neurons in the arcuate nucleus produce different effects on lh pulse patterns in female sheep. Endocrinology 164(11):bqad148. doi: 10.1210/endocr/bqad148 PMID: 37776515 Objective: To test the

Lesions of kndy and kiss1r neurons in the arcuate nucleus produce different effects on lh pulse patterns in female sheep Read More »

Regulation of nociception threshold by norepinephrine through adrenergic α2 receptor in rat models of Parkinson’s disease

Kristen Hartman

Gao Q, Zhang Y, Wang X, Wang R, Zhang L (2024) Regulation of nociception threshold by norepinephrine through adrenergic α2 receptor in rat models of Parkinson’s disease. CNS Neurosci Ther 30(3):e14446. doi: 10.1111/cns.14446 PMID: 37721421 Objective: To investigate the effect of norepinephrine on the activation of brain cells through adrenergic α2 receptor, to regulate the

Regulation of nociception threshold by norepinephrine through adrenergic α2 receptor in rat models of Parkinson’s disease Read More »

Exploring the potential of nanogels: From drug carriers to radiopharmaceutical agents

Kristen Hartman

Kubeil M, Suzuki Y, Casulli MA, Kamal R, Hashimoto T, Bachmann M, Hayashita T, Stephan H (2023) Exploring the potential of nanogels: From drug carriers to radiopharmaceutical agents. Adv Healthc Mater e2301404. doi: 10.1002/adhm.202301404 PMID: 37717209 Summary: This review provides a brief overview of current developments of nanogels in the fields of drug delivery, therapeutic

Exploring the potential of nanogels: From drug carriers to radiopharmaceutical agents Read More »

Validated Antibodies: NGFR & Melanopsin

Targeting Topics / Kristen Hartman

Validated Antibodies targeting NGFR and Melanopsin NGFR Antibodies NGFR (mu p75) Rabbit Polyclonal [AB-N01] AB-N01 also known as mu p75, and the affinity-purified version, AB-N01AP recognize the p75 receptor in mouse. Applications include immunohistochemistry, immunoprecipitation, immunoblotting, flow cytometry, and blocking the function of nerve growth factor receptor. NGFR (ME20.4, p75) Mouse Monoclonal [AB-N07] AB-N07 also known

Validated Antibodies: NGFR & Melanopsin Read More »

Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review)

Kristen Hartman

Thongchot S, Aksonnam K, Thuwajit P, Yenchitsomanus PT, Thuwajit C (2023) Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review). Int J Mol Med 52(3):81. doi: 10.3892/ijmm.2023.5284 PMID: 37477132 Objective: The authors review the mechanisms through which the multiple functions of NCL can participate in the progression of cancer. In addition, the studies

Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review) Read More »

pHast Conjugate Videos

Video / Kristen Hartman

pHast Conjugate Videos Read More »

Screening targeting agents and their cell surface biomarkers for high specificity and rapid internalization via cell death and fluorescence.

Targeting Topics / Kristen Hartman

Screening targeting agents and their cell surface biomarkers for high specificity and rapid internalization via cell death and fluorescence. Ancheta L, Bouajram R, Lappi DA (2018) Society for Neuroscience, San Diego, CA. Abstract Some of the most recent successes in the treatment of cancers or research into passive immunotherapies for neurodegenerative diseases, employ the use

Screening targeting agents and their cell surface biomarkers for high specificity and rapid internalization via cell death and fluorescence. Read More »

PTGFRN as a target for antibody-drug conjugate (ADC) development in mesothelioma and medulloblastoma

Kristen Hartman

Marquez J (2023) PTGFRN as a target for antibody-drug conjugate (ADC) development in mesothelioma and medulloblastoma. Univ Maryland Baltimore Thesis. Objective: To investigate the role of Prostaglandin F2 Receptor Negative (PTGFRN) regulator in cancer progression and develop an antibody-drug conjugate (ADC) targeting PTGFRN for the treatment of mesothelioma and pediatric medulloblastoma. Summary: This dissertation explores

PTGFRN as a target for antibody-drug conjugate (ADC) development in mesothelioma and medulloblastoma Read More »

Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases

Kristen Hartman

Metz M, Kolkhir P, Altrichter S, Siebenhaar F, Levi-Schaffer F, Youngblood BA, Church MK, Maurer M (2023) Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases. Allergy doi: 10.1111/all.15850 PMID: 37605867 Objective: Authors review the role of mast cells (MC) in the pathogenesis of chronic urticaria (CU), explore current therapeutic

Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases Read More »

Author name: Kristen Hartman